Skip to main content

Table 2 Summary of findings for safety outcomes in clinical trials

From: Evaluation of the safety profile of COVID-19 vaccines: a rapid review

Treatment comparison (reference: placebo) Study group (N/total) Pooled RR (95%CI)
Treatment Control
Local reaction (16 vaccines on 5 platforms)
 Inactivated vaccines 10,276/33,901 7674/20,033 0.9 (0.8–1.1)
 RNA vaccines 18,442/20,443 5393/20,428 4.0 (2.9–5.4)
 Non-replicating vector vaccines 3753/6169 1926/6003 2.6 (1.6–4.4)
 Protein subunit vaccines 203/493 45/485 4.5 (3.4–5.9)
 DNA vaccines 66/167 11/50 1.8 (1.0–3.1)
Systemic reaction (16 vaccines on 5 platforms)
 Inactivated vaccines 10,682/33,919 6764/20,033 1.0 (1.0–1.0)
 RNA vaccines 16,440/20,443 10,505/20,429 1.6 (1.5–1.6)
 Non-replicating vector vaccines 3843/6169 2694/6003 1.5 (1.2–1.9)
 Protein subunit vaccines 148/493 105/485 1.4 (1.2–1.8)
 DNA vaccines 49/167 19/50 0.8 (0.5–1.2)
Medically attended events* (2 vaccines on 2 platformss)
 RNA vaccines 140/15,185 83/15,166 1.7 (1.3–2.2)
 Non-replicating vector vaccines 304/21,895 408/21,888 0.7 (0.6–0.9)
SAE* (8 vaccines on 3 platforms)
 Inactivated vaccines 156/33,137 109/19,647 0.8 (0.7–1.0)
 RNA vaccines 223/37,937 201/37,926 1.1 (0.9–1.3)
 Non-replicating vector vaccines 207/50,343 208/39,047 0.8 (0.7–1.0)
SAE related to vaccination* (8 vaccines on 3 platforms)
 Inactivated vaccines 2/33,137 0/19,647 5.0 (0.2–104.0)
 RNA vaccines 10/37,937 4/37,926 2.3 (0.5–10.6)
 Non-replicating vector vaccines 10/50,343 8/39,047 2.4 (0.7–7.8)
  1. AEFI adverse event following immunization, RR random-effect risk ratio, CI confidence intervals, N total number of subjects experiencing one or more AEFI. Per-protocol analysis
  2. *Only considering AEFIs in phase 3 trials